0001415889-24-012554.txt : 20240507 0001415889-24-012554.hdr.sgml : 20240507 20240507201240 ACCESSION NUMBER: 0001415889-24-012554 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240507 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kung Frank CENTRAL INDEX KEY: 0001227255 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34885 FILM NUMBER: 24923884 MAIL ADDRESS: STREET 1: C/O VIVO CAPITAL STREET 2: 505 CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER NAME: FORMER CONFORMED NAME: KUNG FRANK DATE OF NAME CHANGE: 20030414 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYRIS, INC. CENTRAL INDEX KEY: 0001365916 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 550856151 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5885 HOLLIS STREET, SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-0761 MAIL ADDRESS: STREET 1: 5885 HOLLIS STREET, SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: AMYRIS BIOTECHNOLOGIES INC DATE OF NAME CHANGE: 20060613 4 1 form4-05082024_120533.xml X0508 4 2024-05-07 1 0001365916 AMYRIS, INC. AMRS 0001227255 Kung Frank C/O AMYRIS, INC. 5885 HOLLIS STREET, SUITE 100 EMERYVILLE CA 94608 true false false false 0 Common Stock 2024-05-07 4 J 0 6796205 0 D 0 I By Vivo Capital Fund VIII, L.P. Common Stock 2024-05-07 4 J 0 938416 0 D 0 I By Vivo Capital Surplus Fund VIII, L.P. Common Stock 2024-05-07 4 J 0 16207 0 D 0 I By Vivo Capital LLC Pursuant to the Issuer's Third Amended Joint Plan of Reorganization Pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on February 7, 2024 and became effective on May 7, 2024, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. The General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. is Vivo Capital VIII, LLC, of which the Reporting Person is a voting member. The Reporting Person may be deemed to share voting and dispositive power over these shares with four (4) other voting members. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes. Pursuant to an agreement dated November 2, 2017 between the Reporting Person and Vivo Capital LLC ("Vivo Capital"), the Reporting Person agreed to remit the equity compensation received under Issuer's non-employee director compensation program to Vivo Capital if and when such equity compensation becomes vested and/or exercised. In August 2023, pursuant to an agreement between the Reporting Person and the Issuer, the Reporting Person forfeited all unvested restricted stock unit awards and stock option awards granted pursuant to the Issuer's Non-Employee Director Compensation Program. /s/ Frank Kung 2024-05-07